Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

Author's Avatar
Feb 13, 2023

%3Cb%3EVirpax%3Csup%3E%26reg%3B%3C%2Fsup%3E+Pharmaceuticals%2C+Inc.%3C%2Fb%3E (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s non-addictive pain product and its epilepsy product candidate. MET is also utilized in the Company’s viral barrier product candidate. These preclinical toxicology studies were performed to evaluate the safety of the MET platform and to support the IND submission of each product candidate.